# US 2017/0281671 A1 · Non-anticoagulant sulfated or sulfonated synthetic polymers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281671 A1
- Document ID: US20170281671A1
- Status: Published application
- Kind: A1
- Application number: 15/627,332
- Filed: 2017-06-19
- Published: 2017-10-05
- Earliest claimed: 2012-01-30
- Assignees: Baxalta Incorporated
- Applicants: Baxalta Incorporated; Baxalta GmbH
- Inventors: Michael Dockal; Fritz Scheiflinger; Sabine Knappe; Susanne Till; Ton Hai; Paul Sanders
- Web page: https://patentgrep.com/patent/US20170281671A1

## CPC

- A61K 31/795: Polymers containing sulfur
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/37: Coumarins, e.g. psoralen
- A61K 31/7024: Esters of saccharides
- A61K 31/727: Heparin; Heparan
- A61K 38/37: Factors VIII
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro.

## Claims

### Claim at position 1

-22. (canceled)

### Claim 23

A pharmaceutical composition comprising a therapeutically effective amount of a non-anticoagulant, non-saccharide, sulfonated/sulfated synthetic polymer (NASSP); and a pharmaceutically acceptable excipient, wherein the polymer does not comprise —SO2—X group, where X represents a radical derived from arginine or an arginine derivative, bonded by its amino function —NH— to the radical —SO2—.

### Claim 24 (depends on 23)

The composition according to claim 23, wherein the polymer has a formula selected from:
wherein
R1 is selected from H, substituted or unsubstituted alkyl and sulfonated aryl;
R2 is selected from H, substituted or unsubstituted alkyl, sulfonate and sulfate, such that at least one of R1 and R2 is a moiety which is a member selected from sulfonate and sulfate; and
the index n represents an integer sufficient to provide a polymer of a molecular weight of from about 7 kDa to about 300 kDa.

### Claim 25 (depends on 24)

The composition according to claim 24, wherein
R1 is:
in which
R3 is selected from H and OR4;
R4 is selected from H, and substituted or unsubstituted alkyl; and
s is an integer selected from 0, 1, 2, 3, 4 or greater.

### Claim 26 (depends on 23)

A unit dosage formulation for use in a method for treating a subject in need of enhanced blood coagulation, characterized in that the method comprises administering a therapeutically effective amount of a composition comprising a non-anticoagulant, non-saccharide sulfonated/sulfated polymer to the subject, the unit dosage formulation comprising the polymer according to claim 23 in a therapeutically effective amount.

### Claim 27 (depends on 26)

The unit dosage formulation according to claim 26, comprising from about 0.5 mg to about 1000 mg of the non-anticoagulant, non-saccharide sulfonated/sulfated polymer.

### Claim 28 (depends on 26)

The unit dosage formulation according to claim 26 wherein the polymer is in an amount sufficient to provide a dosage from about 0.01 mg/kg to about 100 mg/kg.

### Claim 29 (depends on 26)

The unit dosage formulation according to claim 26, wherein the polymer is present in the formulation in an amount sufficient to enhance blood coagulation in a subject to whom the unit dosage formulation is administered.

### Claim 30 (depends on 26)

The unit dosage formulation according to claim 26, wherein the unit dosage formulation is an oral unit dosage formulation.

### Claim 31

A composition for treating a subject in need of enhanced blood coagulation, comprising a non-anticoagulant, non-saccharide sulfonated/sulfated polymer, characterized in that a therapeutically effective amount of the composition is administered to said subject, wherein the polymer does not comprise —SO2—X group, where X represents a radical derived from arginine or an arginine derivative, bonded by its amino function —NH— to the radical —SO2—.

### Claim 32 (depends on 31)

The composition according to claim 31, characterized in that the composition is administered to the subject at a dosage of about 0.01 mg/kg to about 100 mg/kg of the polymer.

### Claim 33 (depends on 31)

The composition according to claim 31, characterized in that the composition is administered as a unit dosage formulation.

### Claim 34 (depends on 31)

The composition according to claim 31, characterized in that the composition is administered orally.

### Claim 35 (depends on 31)

The composition according to claim 31, wherein the subject has a bleeding disorder selected from the group consisting of a chronic or acute bleeding disorder, a congenital coagulation disorder caused by a blood factor deficiency, and an acquired coagulation disorder.

### Claim 36 (depends on 35)

The composition according to claim 35, wherein the blood factor deficiency is a deficiency of one or more factors selected from the group consisting of Factor V, Factor VII, Factor VIII, Factor IX, Factor XI, Factor XII, Factor XIII, and von Willebrand Factor.

### Claim 37 (depends on 31)

The composition according to claim 31, characterized in that said composition is administered to said subject prior to surgery or other invasive procedure.

### Claim 38 (depends on 31)

The composition according to claim 31, characterized in that an agent is further administered in combination with the composition, the agent selected from the group consisting of a procoagulant, an activator of the intrinsic coagulation pathway, an activator of the extrinsic coagulation pathway, a non-anticoagulant sulfated/sulfonated polysaccharide (NASP), and a second non-anticoagulant, non-saccharide sulfonated/sulfated polymer, which has a structure different from the non-anticoagulant, non-saccharide sulfonated/sulfated polymer.

### Claim 39 (depends on 38)

The composition of claim 38, wherein the agent is selected from the group consisting of tissue factor, Factor II, Factor V, Factor Va, Factor VII, Factor VIIa, Factor VIII, Factor VIIIa, Factor X, Factor X, Factor Xa, Factor IXa, Factor XI, Factor XIa, Factor XII, Factor XIIa, Factor XIII, prekallikrein, HMWK, and von Willebrand Factor.

### Claim 40 (depends on 38)

The composition of claim 38, wherein the anticoagulant is selected from the group consisting of heparin, a coumarin derivative, such as warfarin or dicumarol, Tissue Factor Pathway Inhibitor (TFPI), antithrombin III, lupus anticoagulant, nematode anticoagulant peptide (NAPc2), active-site blocked Factor VIIa (Factor VIIai), Factor IXa inhibitors, Factor Xa inhibitors, including fondaparinux, idraparinux, DX-9065a, and razaxaban (DPC906), inhibitors of Factors Va and VIIIa, including activated protein C (APC) and soluble thrombomodulin, thrombin inhibitors, including hirudin, bivalirudin, argatroban, and ximelagatran, and an antibody that binds a coagulation factor.

### Claim 41 (depends on 38)

The composition of claim 38, wherein the anticoagulant is an antibody that binds a coagulation factor selected from the group consisting of Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XIII, Factor II, Factor XI, Factor XII, von Willebrand Factor, prekallikrein, and HMWK.

### Claim 42

A composition for inhibiting Tissue Factor Pathway Inhibitor (TFPI) activity in a subject, the composition comprising a non-anticoagulant, non-saccharide sulfonated/sulfated polymer, characterized in that an amount of the composition sufficient to inhibit the TFPI is administered to the subject, wherein the polymer does not comprise —SO2—X group, where X represents a radical derived from arginine or an arginine derivative, bonded by its amino function —NH— to the radical —SO2—.

### Claim 43

A composition for inhibiting TFPI activity in a biological sample comprising a sufficient amount of a non-anticoagulant, non-saccharide sulfonated/sulfated polymer to inhibit the TFPI activity, wherein the polymer does not comprise —SO2—X group, where X represents a radical derived from arginine or an arginine derivative, bonded by its amino function —NH— to the radical —SO2—.

### Claim 44

An in vitro method of measuring acceleration of blood clotting by a non-anticoagulant, non-saccharide, sulfonated/sulfated polymer in a biological sample, the method comprising: a) combining the biological sample with a composition comprising the polymer, b) measuring the clotting time of the biological sample, c) comparing the clotting time of the biological sample to the clotting time of a corresponding biological sample not exposed to the polymer, wherein a decrease in the clotting time of the biological sample exposed to the polymer is indicative of a polymer that accelerates the clotting, wherein the polymer does not comprise —SO2—X group, where X represents a radical derived from arginine or an arginine derivative, bonded by its amino function —NH— to the radical —SO2—.
